Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial

The Lancet Infectious Diseases

Volumn 17, Issue 5, 2017, Pages 528-537

  Huttner, Angela ^a   Hatz, Christoph ^b,c   van den Dobbelsteen, Germie ^d   Abbanat, Darren ^e   Hornacek, Alena ^f   Frölich, Rahel ^f   Dreyer, Anita M ^f   Martin, Patricia ^f   Davies, Todd ^e   Fae, Kellen ^d   van den Nieuwenhof, Ingrid ^d   Thoelen, Stefan ^d   de Vallière, Serge ^g   Kuhn, Anette ^h   Bernasconi, Enos ⁱ   Viereck, Volker ^j   Kavvadias, Tilemachos ^k   Kling, Kerstin ^c   Ryu, Gloria ^l   Hülder, Tanja ^m   Gröger, Sabine ⁿ   Scheiner, David ^o   Alaimo, Cristina ^f   Harbarth, Stephan ^a   Poolman, Jan ^d   Fonck, Veronica Gambillara ^f   more..

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d Janssen Research and Development   (Netherlands)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f LimmaTech Biologics   (Switzerland)

^g POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^j Kantonsspital Frauenfeld   (Switzerland)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

^l CANTONAL HOSPITAL AARAU   (Switzerland)

^m CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁿ LUZERNER KANTONSSPITAL   (Switzerland)

^o UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI VACCINE; IMMUNOGLOBULIN G; PLACEBO;

ADULT; ADVERSE OUTCOME; AGED; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; CONTROLLED STUDY; ESCHERICHIA COLI INFECTION; EXTRAINTESTINAL PATHOGENIC ESCHERICHIA COLI; FEMALE; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEROTYPE; SINGLE BLIND PROCEDURE; URINARY TRACT INFECTION; VACCINE IMMUNOGENICITY; CLINICAL TRIAL; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; VACCINATION;

ADULT; AGED; ESCHERICHIA COLI VACCINES; EXTRAINTESTINAL PATHOGENIC ESCHERICHIA COLI; FEMALE; HUMANS; IMMUNOGENICITY, VACCINE; MIDDLE AGED; SINGLE-BLIND METHOD; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; VACCINATION;

EID: 85013648004     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30108-1     Document Type: Article

References (30)

1. 1 Laupland, KB, Church, DL, Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 27 (2014), 647–664.
2. 2 Flores-Mireles, AL, Walker, JN, Caparon, M, Hultgren, SJ, Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13 (2015), 269–284.
3. 3 Weiner, LM, Webb, AK, Limbago, B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 37 (2016), 1288–1301.
4. 4 Stewardson, AJ, Allignol, A, Beyersmann, J, et al. The health and economic burden of bloodstream infections caused by antimicrobial susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals: a multicentre retrospective cohort study. Eurosurveillance 21 (2016), 30–319.
5. 5 Boucher, HW, Talbot, GH, Benjamin, DK Jr, et al. 10 × '20 progress—development of new drugs active against gram-negative bacilli. An update from the Infectious Diseases Society of America. Clin Infect Dis 56 (2013), 1685–1694.
6. 6 Torio, CM, Moore, BJ, National inpatient hospital costs: the most expensive conditions by payer, 2013. 2016: 1–15, 2016, Agency for Healthcare Research and Quality, Rockville, MD.
7. 7 Miajlovic, H, Smith, SG, Bacterial self-defence. How Escherichia coli evades serum killing. FEMS Microbiol Lett 354 (2014), 1–9.
8. 8 Sarkar, S, Ulett, GC, Totsika, M, Phan, M, Schembri, MA, Forestier, C, Role of capsule and O antigen in the virulence of uropathogenic Escherichia coli. PLoS One, 9, 2014, e94786.
9. 9 Prymula, R, Peeters, P, Chrobok, V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367 (2006), 740–748.
10. 10 Pichichero, ME, Meningococcal conjugate vaccine in adolescents and children. Clin Pediatr (Phila) 44 (2005), 479–489.
11. 11 Reinert, RR, Paradiso, P, Fritzell, B, Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines 9 (2010), 229–236.
12. 12 Dagan, R, Poolman, JT, Zepp, F, Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines 7 (2008), 97–115.
13. 13 Cryz, SJ Jr, Cross, AS, Sadoff, JC, Wegmann, A, Que, JU, Furer, E, Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans. J Infect Dis 163 (1991), 1040–1045.
14. 14 Cross, A, Artenstein, A, Que, J, et al. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 170 (1994), 834–840.
15. 15 Poolman, JT, Wacker, M, Extraintestinal pathogenic Escherichia coli, a common human pathogen. Challenges for vaccine development and progress in the field. J Infect Dis 213 (2016), 6–13.
16. 16 Wacker, M, Linton, D, Hitchen, PG, et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E coli. Science 298 (2002), 1790–1793.
17. 17 Kowarik, M, Numao, S, Feldman, MF, et al. N-linked glycosylation of folded proteins by the bacterial oligosaccharyltransferase. Science 314 (2006), 1148–1150.
18. 18 Riddle, MS, Kaminski, RW, Di Paolo, C, et al. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study. Clin Vaccine Immunol 23 (2016), 908–917.
19. 19 Van den Dobbelsteen, Germie, PJM, Faé, KC, et al. Immunogenicity and safety of a tetravalent E coli O-antigen bioconjugate vaccine in animal models. Vaccine 34 (2016), 4152–4160.
20. 20 Dagan, R, Poolman, J, Siegrist, CA, Glycoconjugate vaccines and immune interference. A review. Vaccine 28 (2010), 5513–5523.
21. 21 Gupta, K, Hooton, TM, Naber, KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52 (2011), e103–e120.
22. 22 Hatz, CF, Bally, B, Rohrer, S, et al. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults. A single blind, partially randomized phase I study. Vaccine 33 (2015), 4594–4601.
23. 23 Destefano, F, Pfeifer, D, Nohynek, H, Safety profile of pneumococcal conjugate vaccines. systematic review of pre- and post-licensure data. Bull World Health Organ 86 (2008), 373–380.
24. 24 Rinderknecht, S, Bryant, K, Nolan, T, et al. The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY). Hum Vaccin Immunother 8 (2012), 304–311.
25. 25 Abraham, SN, Miao, Y, The nature of immune responses to urinary tract infections. Nat Rev Immunol 15 (2015), 655–663.
26. 26 Siber, GR, Chang, I, Baker, S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25 (2007), 3816–3826.
27. 27 Juergens, C, Patterson, S, Trammel, J, et al. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization. Clin Vaccine Immunol 21 (2014), 1277–1281.
28. 28 Rogers, BA, Sidjabat, HE, Paterson, DL, Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 66 (2011), 1–14.
29. 29 Rossignol, L, Pelat, C, Lambert, B, Flahault, A, Chartier-Kastler, E, Hanslik, T, A method to assess seasonality of urinary tract infections based on medication sales and google trends. PLoS One, 8, 2013, e76020.
30. 30 Fortanier, AC, Venekamp, RP, Boonacker, CW, et al. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev, 2014 CD001480.